Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simdax to reduce LCOS in low LVEF cardiac surgery patients
NCT04179604Phase 3
Key facts
- Status
- Unknown
- Start
- Jun 2020
- Primary completion
- Jan 2022
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- levosimendan
- Conditions
- low cardiac output syndrome (LCOS)
01
Overview
Phase 3, randomised, triple-blind trial of levosimendan in low cardiac output syndrome (LCOS). Primary endpoint: Low Cardiac Output Syndrome at 30 days. Status: unknown.
02
Design
- Study design
- RandomizedTriple-blind
03
Who it enrols
Adults with LVEF ≤ 35% scheduled for elective AVR or CABG, excluding those with severe renal/hepatic failure, hemodynamic instability, or previous cardiac surgery.
04
Endpoints
Primary
Low Cardiac Output Syndrome
Beyond the preview
Go deeper on NCT04179604.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179604.